• According to the World Health Organization (2016), an estimated 422 million adults worldwide were living with diabetes in 2014 (compared with 108 million in 1980). 1
• 8.5% of adults over 18 years of age was suffering from diabetes in 2014 (4.7% in 1980). 2
• Worldwide, 1 in 7 adults suffers from diabetes, while among adults 60 years of age and older, the prevalence is twice as high. 3
• In diabetic patients, an increased risk of inflammation of the tissues surrounding the tooth may cause periodontitis eventually leading to tooth loss. 4

### Study design

<table>
<thead>
<tr>
<th>Study duration</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Years</td>
<td>Single tooth gap in the anterior and premolar zone of the maxilla and mandible</td>
</tr>
</tbody>
</table>

**Patients**

27* non-diabetic, 3.3 mm Straumann® Roxolid® SLActive®

*available for 2 years follow-up

**well-controlled (HbA1c level)

**Implant**

3.3 mm Straumann® Roxolid® SLActive®

### Results

#### Similar bone loss***

**Mean crestal bone level change after 2 years**

<table>
<thead>
<tr>
<th>non-diabetic</th>
<th>diabetic (DM2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>-1</td>
</tr>
<tr>
<td>-0.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>-0.4</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

*** non-diabetic: -0.43 ±0.47 mm, diabetic: -0.48 ±0.50 mm

After 2 years, no differences between the two treatment groups were found.

### Excellent performance

Implant success and survival rates of the diabetic and the non-diabetic groups after 2 years follow-up.

100 % non-diabetic

100 % diabetic (DM2)

### Conclusions

• Straumann® Roxolid® SLActive® narrow diameter implants, placed in both diabetic and healthy patients have shown excellent survival rates and similar bone remodeling after 2 years.

• SLActive® implants can be used in diabetic patients with a high predictability of success.

**References**